Azacitidine, Venetoclax, and Revumenib for Newly Diagnosed NPM1-Mutated or KMT2A-Rearranged AML.

doi:10.1200/JCO-25-00914

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Azacitidine, Venetoclax, and Revumenib for Newly Diagnosed NPM1-Mutated or KMT2A-Rearranged AML.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 10 Aug 2025

Zeidner Joshua F, Lin Tara L, Welkie Rina Li, Curran Emily, Koenig Kristin, Stock Wendy, Madanat Yazan F, Swords Ronan, Baer Maria R, Blum William, Stein Eytan M, Olin Rebecca L, Schiller Gary, Nichols Angela, Odenike Olatoyosi, Traer Elie, Lachowiez Curtis, Duong Vu H, Hochman Michael J, Cai Sheng F, Smith Catherine, Stefanos Mona, Martycz Molly, Huang Ying, Rosenberg Len, Marcus Sonja, Chen Timothy L, Yocum Ashley O, Druker Brian J, Levine Ross L, Borate Uma, Byrd John C, Mims Alice S

Abstract excerpt

PURPOSE: Azacitidine and venetoclax is a standard frontline treatment regimen for newly diagnosed older adults with AML; however, long-term outcomes remain poor. Revumenib is an oral menin inhibitor with clinical activity in AML patients with nucleophosmin-1 mutation (NPM1m) or lysine methyltransferase 2A rearrangements (KMT2Ar). METHODS: We conducted a phase I dose-escalation and expansion study of azacitidine,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzamides

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Bridged Bicyclo Compounds, Heterocyclic

Share to Gene Rearrangement

Share to Histone-Lysine N-Methyltransferase

Share to Myeloid-Lymphoid Leukemia Protein

Share to Nucleophosmin

Share to Spiro Compounds

Share to Sulfonamides

Source

Open in PubMed Open full text

Identifiers

PMID: 40504618
DOI: 10.1200/JCO-25-00914
PMCID: PMC12316144

Genes

KMT2A
NPM1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Azacitidine, Venetoclax, and Revumenib for Newly Diagnosed NPM1-Mutated or KMT2A-Rearranged AML.PMID 40504618Read ↗

Menin inhibition with revumenib for NPM1-mutated relapsed or refractory acute myeloid leukemia: the AUGMENT-101 study.Semantic proximity Read ↗

The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemiaSemantic proximity Read ↗

Menin inhibitors for patients with relapsed/refractory acute myeloid leukemia (AML): a systematic review and meta-analysis.Semantic proximity Read ↗

Ziftomenib in Relapsed or Refractory NPM1-Mutated AML.Semantic proximity Read ↗

Revumenib for patients with acute leukemia: a new tool for differentiation therapySemantic proximity Read ↗

The promise of menin inhibitors: from approval to triplet regimens.Semantic proximity Read ↗

Emerging drug profile: menin inhibitors in NPM1-mutated and KM2A-rearranged acute myeloid leukemia.Semantic proximity Read ↗

The Menin Inhibitor SNDX-5613 (revumenib) Leads to Durable Responses in Patients (Pts) with KMT2A-Rearranged or NPM1 Mutant AML: Updated Results of a Phase (Ph) 1 StudySemantic proximity Read ↗

Venetoclax-based therapy versus hypomethylating agents alone in unfit patients with newly diagnosed acute myeloid leukemia: a real-world study from the PETHEMA registrySemantic proximity Read ↗

Menin Inhibitors: A New Era of Targeted Therapies in Acute Myeloid Leukemia.Semantic proximity Read ↗

Advancements and Challenges in the Treatment of AML.Semantic proximity Read ↗

Latest Insights and Progress in the Clinical Management of Elderly Patients with Acute Myeloid Leukemia: From Genetic Advancements to Targeted TreatmentsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.